✦ LIBER ✦

PCN36 ECONOMIC EVALUATION OF ERLOTINIB, DOCETAXEL AND PEMETREXEDAS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A COST-MINIMIZATION IN ITALIAN HOSPITALS

✍ Scribed by S Capri; A Morabito; G Carillio; F Grossi; R Longo; G Cerea; F Rossetti

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN10 COST-EFFCTIVENESS ANALYSIS OF ERLO

✍ TC Hsia; GC Chang; YM Chen; MC Lin; WC Su; CM Tsai; CM Tsai; L Yang; J Creeden 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

PCN32 COST-MINIMISATION ANALYSIS OF ERLO

✍ S Stefani; MG Saggia; EA Santos 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

PCN90 Cost-Effectiveness Analysis of Erl

✍ Nguyen, T.T.T.; Yagudina, R.; Kulikov, A. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PCN58 A COST UTILITY ANALYSIS OF ERLOTIN

✍ PA Bradbury; R Jang; P Isogai; R Ng; N Mittmann; W Evans; FA Shepherd; NB Leighl 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

PCN50 COST-MINIMIZATION ANALYSIS OF ERLO

✍ E Suchankova; T Doležal 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

PCN25 COST-EFFECTIVENESS ANALYSIS OF ERL

✍ Kim, YG; Lee, EK 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB